Recent molecular studies indicate that aerobic glycolysis plays an important role in tumorigenesis and is a valid target for cancer therapy. Although 2-deoxyglucose (2-DG) is well characterized as a glycolytic inhibitor, we recently discovered that it activates a prosurvival oncoprotein, AKT, through PI3K. In this study, we discovered that 2-DG treatments disrupted the binding between insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP3) so that the free form of IGF-1 could be released from the IGF-1⅐IGFBP3 complex to activate IGF-1 receptor (IGF1R) signaling. Because IGF1R signaling is involved, PI3K/AKT constitutes only one of the prosurvival pathways that are activated by 2-DG treatment; we validated that MEK-ERK signaling was also induced in an IGF1R-dependent manner in some cancer cell lines. Furthermore, our phospho-specific antibody microarray analysis indicated that 2-DG up-regulated the phosphorylation of 64 sites within various signaling pathways in H460 cells. Chemical inhibition of IGF1R reduced 57 of these up-regulations. These data suggest that 2-DG-induced activation of many survival pathways can be jointly attenuated through IGF1R inhibition. Our in vitro analysis demonstrated that treatment with a combination of subtoxic doses of 2-DG and the IGF1R inhibitor II reduced cancer cell proliferation 90% and promoted significant apoptosis.Cancer cells display high rates of aerobic glycolysis in comparison with their nontransformed counterparts (i.e. the Warburg effect (1)). Whether increased aerobic glycolysis drives tumor formation or merely represents a byproduct of oncogenic transformation has been a subject of controversy. Two recent studies demonstrated that the Warburg effect can be reversed in some cancer cells by either the depletion of lactate dehydrogenenase A or switching pyruvate kinase expression from M2 to M1 isoform (2, 3). Interestingly, the reversal of the Warburg effect correlates with a reduction in the ability of the isogenic cancer cells to form tumors in nude mouse xenografts.Viewed in combination, these observations appeared to indicate that tumor cells preferentially use glucose for purposes other than oxidative phosphorylation and that aerobic glycolysis is a valid target for cancer therapeutics.Targeting glycolysis for cancer treatment has been explored previously as a therapeutic approach (4, 5). Of all the glycolysis inhibitors that were evaluated, 2-deoxyglucose (2-DG) 3 is the one that has been best characterized in animal model studies and human clinical trials (6 -8). It is converted by hexokinase to phosphorylated 2-DG, which becomes trapped inside the cell and inhibits hexokinase (9). As a direct consequence of 2-DG treatment, intracellular ATP is depleted (10, 11), which ultimately suppresses cell proliferation in vitro (12, 13). Nonetheless, the implementation of 2-DG as an anticancer agent in vivo has been a disappointment. Whereas 2-DG suppresses cell growth in vitro, studies using xenografts indicate that 2-DG treatment, when provided as a singl...
Salinomycin is perhaps the first promising compound that was discovered through high throughput screening in cancer stem cells. This novel agent can selectively eliminate breast and other cancer stem cells, though the mechanism of action remains unclear. In this study, we found that salinomycin induced autophagy in human non-small cell lung cancer (NSCLC) cells. Furthermore, we demonstrated that salinomycin stimulated endoplasmic reticulum stress and mediated autophagy via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis. Moreover, we found that the autophagy induced by salinomycin played a prosurvival role in human NSCLC cells and attenuated the apoptotic cascade. We also showed that salinomycin triggered more apoptosis and less autophagy in A549 cells in which CDH1 expression was inhibited, suggesting that the inhibition of autophagy might represent a promising strategy to target cancer stem cells. In conclusion, these findings provide evidence that combination treatment with salinomycin and pharmacological autophagy inhibitors will be an effective therapeutic strategy for eliminating cancer cells as well as cancer stem cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.